Abramson Cancer Center at Penn Medicine
This is a single-center, non-interventional biospecimen collection protocol that accompanies C-FLASH-01 (Protocol IBA-04-UP, IDE G260113), a pilot trial of ultra-high dose rate proton reirradiation (ConformalFLASH) for head and neck cancer. Blood and saliva will be collected from up to 10 participants enrolled on the C-FLASH-01 trial at three time points: 1) within 4 weeks before the start of radiotherapy, 2) within 3 days of the last day of radiotherapy, and 3) within 4 months after completion of radiotherapy.
The study team hypothesize that biomarkers measurable in blood and saliva, including but not limited to cell-free DNA and cytokines, change over the course of ConformalFLASH reirradiation and are associated with normal tissue response/toxicity. This protocol does not include a study intervention; all radiotherapy is delivered under the separately approved parent protocol (Protocol IBA-04-UP, IDE G260113).
Inclusion Criteria: * Enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) and planned to receive ConformalFLASH reirradiation * Male or female, aged 18 years or older * Provision of signed and dated informed consent for this biospecimen protocol * Stated willingness to comply with the specimen collection Exclusion Criteria: * Any condition that, in the judgment of the investigator, makes repeated peripheral venipuncture unsafe or infeasible * Inability to provide informed consent
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.